CN Patent

CN112533593A — 含有阿塞那平的透皮治疗系统

Assigned to LTS Lohmann Therapie Systeme AG · Expires 2021-03-19 · 5y expired

What this patent protects

本发明涉及用于透皮施用阿塞那平的透皮治疗系统(TTS)，其包括含有治疗有效量的阿塞那平的自粘层结构；用于治疗方法的此类阿塞那平TTS；此类TTS的制备方法以及用于治疗方法的阿塞那平和含有阿塞那平的透皮治疗系统；并且涉及通过透皮施用阿塞那平治疗人类患者的方法。

USPTO Abstract

本发明涉及用于透皮施用阿塞那平的透皮治疗系统(TTS)，其包括含有治疗有效量的阿塞那平的自粘层结构；用于治疗方法的此类阿塞那平TTS；此类TTS的制备方法以及用于治疗方法的阿塞那平和含有阿塞那平的透皮治疗系统；并且涉及通过透皮施用阿塞那平治疗人类患者的方法。

Drugs covered by this patent

donepezil-hydrochloride (DONEPEZIL HYDROCHLORIDE)

Patent Metadata

Patent number: CN112533593A
Jurisdiction: CN
Classification: —
Expires: 2021-03-19
Drug substance claim: No
Drug product claim: No
Assignee: LTS Lohmann Therapie Systeme AG
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.